Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 20,669,196 shares, a decline of 12.0% from the February 15th total of 23,477,967 shares. Based on an average trading volume of 10,166,508 shares, the short-interest ratio is presently 2.0 days. Currently, 1.9% of the company’s shares are sold short.
In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 5,041 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $17.88, for a total transaction of $90,133.08. Following the completion of the sale, the vice president now owns 17,162 shares of the company’s stock, valued at approximately $306,856.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah A. Griffin sold 4,107 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $69,326.16. Following the sale, the insider now directly owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The disclosure for this sale can be found here. Insiders have sold a total of 16,173 shares of company stock valued at $273,316 in the last ninety days. Company insiders own 0.43% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. lifted its position in Teva Pharmaceutical Industries by 27.6% in the 4th quarter. American Century Companies Inc. now owns 1,657,439 shares of the company’s stock valued at $25,558,000 after acquiring an additional 358,110 shares in the last quarter. Geode Capital Management LLC lifted its position in Teva Pharmaceutical Industries by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 3,126,584 shares of the company’s stock valued at $48,115,000 after acquiring an additional 279,286 shares in the last quarter. Norges Bank bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $146,130,000. Actinver Wealth Management Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $2,137,000. Finally, FMR LLC lifted its position in Teva Pharmaceutical Industries by 44.0% in the 4th quarter. FMR LLC now owns 35,248,665 shares of the company’s stock valued at $543,534,000 after acquiring an additional 10,766,729 shares in the last quarter. 66.42% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have commented on TEVA. UBS Group began coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, March 7th. They set a “buy” rating and a $22.00 target price for the company. Morgan Stanley lowered shares of Teva Pharmaceutical Industries from an “overweight” rating to an “equal weight” rating and set a $17.00 target price for the company. in a report on Wednesday, March 6th. Mizuho lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. Credit Suisse Group reduced their price target on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, February 14th. Finally, Raymond James raised shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 price target on the stock in a research report on Thursday, February 14th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average target price of $21.21.
Shares of NYSE TEVA opened at $16.51 on Monday. The firm has a market cap of $16.78 billion, a PE ratio of 5.90, a PEG ratio of 2.96 and a beta of 1.34. Teva Pharmaceutical Industries has a twelve month low of $14.59 and a twelve month high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 1.69.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, February 13th. The company reported $0.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.53. The company had revenue of $4.56 billion for the quarter, compared to analysts’ expectations of $4.52 billion. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The business’s quarterly revenue was down 15.5% compared to the same quarter last year. During the same period last year, the firm posted $0.93 earnings per share. As a group, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Short Interest Update” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2019/03/18/teva-pharmaceutical-industries-ltd-teva-short-interest-update.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Strike Price
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.